Clinical trials
Diffuse Large B Cell Lymphoma clinical trials
Below are recruiting diffuse large b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 381 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70 - NCT05253495RecruitingPhase 2
Targeted immunotherapy added to chemotherapy and radiation for lymphoma
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
Birmingham, AlabamaAges 3–39 - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT03125642RecruitingPhase 2
Auto stem cell transplant for lymphoma after chemo
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Minneapolis, MinnesotaAges Up to 75 years - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT05676450Recruiting
Test blood DNA to find lymphoma changes and leftover disease
This study checks a blood test that looks for small DNA fragments (“cell-free DNA”) to find cancer changes that could guide treatment in diffuse large B-cell lymphoma. It also looks for “minimal residual disease,” meaning tiny amounts of lymphoma that may remain after treatment, and whether this test works across community cancer centers in Texas.
Houston, TexasAges 18 years+ - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT07574346RecruitingEarly Phase 1
IASO207 injection for relapsed or resistant B-cell lymphoma
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
BeijingAges 18–75 - NCT01676805Recruiting
Collecting tissue samples for lymphoma research
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
Bethesda, MarylandAges 18 years+ - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT04586478RecruitingPhase 2
CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Beijing, Beijing MunicipalityAges 18–75 - NCT06585124Recruiting
Study of t cells in lymphoma patients with HLH
This study looks at specific immune cells (T cells) in people who have a rare condition called Hemophagocytic Lymphohistiocytosis (HLH) together with an aggressive lymphoma. It aims to better understand how these cells behave, which may lead to improved diagnosis or treatment.
Rome, LazioAges 18 years+ - NCT07456371RecruitingPhase 1
PIC1 injection for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Wuhan, HubeiAges 18–75 - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse large b cell lymphoma?
- Yes. Clin2 currently lists 381 recruiting diffuse large b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse large b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse large b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Large B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.